April 2026 Vol 19, No 2
Clinical trial recruitment and retention remain challenging in the quest to bring innovative therapies to all patients in need.
The conversation around work-life balance in healthcare can sometimes feel like a luxury, or worse, a myth. But in oncology pharmacy, balance isn’t about perfection or strict boundaries; it’s about sustainability.
Original Research, Adverse Events, Disparities in Oncology, Dose Escalation/Reduction, Immunotherapy, Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and Europe.
Laura Fan Sun, PharmD, BCOP; Natalie Brumwell, PharmD; Kevin Hall, PharmD; Kristina Murphy, PharmD; Jeffrey Switchenko, PhD; Yichun Cao, MPH; Vikas Gupta, MD, PhD; Madhav Dhodapkar, MBBS; Nisha Joseph, MD; Craig Hofmeister, MD, MPH; Jonathan Kaufman, MD; Ajay Nooka, MD, MPH, FACP; Sagar Lonial, MD; Kathryn Maples, PharmD
With major reimbursement and coverage changes occurring in 2026, oncology practices are closely watching federal policy developments that could affect everything from prior authorization workflows to drug reimbursement and patient coverage stability.